A total of 32 relapsed patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib received pemetrexed 500 mg/m 2 by the intravenous administration on the first day, with 21 days as a cycle. Dexamethasone, folic acid and vitamin B 12 were applied to relieve the drug toxicity. The objective response rate was estimated by Response Evaluation Criteria in Solid Tumors (RECIST) and the toxicity was estimated by National Cancer Institute Common Toxicity Criteria (version 3.0).
Results For a total of 32 patients, 4 patients reached partial response (PR), constituting a total of 12.5%; 11 patients reached stable disease (SD), constituting a total of 34.4%; 17 patients reached progressive disease (PD), constituting a total of 53.1%.
The median progression free survival (PFS) was 2.7 months. The median overall survival (OS) was 11.0 months. One-year survival rate was 37.5%. The most common adverse events (AEs) were myelosuppression with grade I and grade II toxicity. Other adverse events were tolerated. Conclusion Pemetrexed was clinically beneficial for the patients with pulmonary adenocarcinoma after the failure of chemotherapy and gefitinib. www.lungca.org 
